What Has Been the Growth of the End Stage Renal Disease (ESRD) Drug Market So Far?
The end stage renal disease (esrd) drug market has seen considerable growth due to a variety of factors.
• The drug market for end stage renal disease (ESRD) has been experiencing swift growth in the last few years. The market size is predicted to expand from $131.41 billion in 2024 to an impressive $149.88 billion by 2025, projecting an annual growth rate (CAGR) of 14.1%. Factors contributing to historical growth include a rising number of ESRD cases, an aging population, increased access to healthcare services, supportive government initiatives and policies, and a growing acceptance of renal replacement therapies.
What Are the Future Growth Projections for the End Stage Renal Disease (ESRD) Drug Market By 2029?
The End Stage Renal Disease (ESRD) Drug market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to witness accelerated growth over the coming years, the market size of the end stage renal disease (ESRD) drug is projected to reach $268.44 billion in 2029, visualizing a compound annual growth rate (CAGR) of 15.7%.
This growth expected in the forecasted timeframe can be credited to the advent of newer therapeutic strategies and drug advancements, increased health care expenditures, the mounting global load of chronic kidney diseases, bespoke medicinal approaches, regulatory endorsements, and expedited sanctioning processes. The key trends during the projected timeline are likely to include an escalated occurrence of end stage renal disease, progress in therapeutic modalities, amplified focus on precision medicine, inclination towards combination therapies, and the incorporation of technology in healthcare.
What Are The Core Factors Supporting Growth In The End Stage Renal Disease ESRD Drug Market?
The upswing in obesity and diabetes incidences is anticipated to boost the expansion of the end-stage renal disease (ESRD) drug market. Obesity is characterized by abnormal or excess adipose tissue accumulation that risks health, whereas diabetes is a persistent ailment that occurs when the pancreas fails to produce sufficient insulin or the body can't effectively use the insulin it produces. In the case of renal disease patients, controlling fluid and electrolyte balance, blood pressure, and the elimination of waste through dialysis can enhance overall health, potentially leading to weight loss and improved blood sugar stability. For instance, as stated by the World Obesity, a national and regional association network based in the US dedicated to obesity research and management, in March 2022, the obesity population is projected to increase to 892 million by 2025 and further to 1,025 million by 2030. Moreover, the National Health Service, a publicly funded healthcare system based in the UK, estimated in February 2023 that by 2030, the number of diabetes patients in the UK could surge to 5.5 million, affecting nearly 9% of the population. Hence, the escalating incidences of obesity and diabetes are predicted to stimulate the ESRD drug market.
What Are The Major Segments Within The Global End Stage Renal Disease ESRD Drug Market?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Pre-Book The End Stage Renal Disease ESRD Drug Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The End Stage Renal Disease ESRD Drug Market?
A significant trend that is intensifying in the end-stage renal disease (ESRD) drug market is product innovation. To stay competitive in the market, major corporations involved in the ESRD drug market are prioritizing the development of ground-breaking solutions. In a notable instance from April 2022, UK-based pharmaceutical and biotech company GlaxoSmithKline PLC shared that its New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was given the green light by the US Food and Drug Administration (FDA). This was targeted at potentially treating patients with chronic kidney disease anemia (CKD). This advanced product leverages unique, Nobel-prize winning science that unravels how cells detect and adapt to the presence of oxygen.
Who Are the Key Players In The End Stage Renal Disease ESRD Drug Market?
Major companies operating in the end stage renal disease (ESRD) drug market include:
• Pfizer Inc.
• AstraZeneca plc
• Sanofi SA
• Astellas Pharma Inc.
• Novartis AG
• Fresenius SE & Co. KGaA
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Kissei Pharmaceutical Co. Ltd.
• Baxter International Inc.
• AbbVie Inc.
• Amgen Inc.
• Akebia Drugs Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• B. Braun SE
• Asahi Kasei Medical Co. Ltd.
• Nikkiso Co. Ltd.
• Abbott Laboratories
• Merck Co. & KGaA
What Is The Most Dominant Region In The End Stage Renal Disease ESRD Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
